The German pharmaceutical company Fresenius has taken another step in its strategic realignment by selling its Chilean subsidiary Laboratorio Sanderson S.A. and the associated IV production facility in Santiago de Chile to the Peruvian pharmaceutical company Medifarma. Fresenius announced this on Monday.

The sale is made within the framework of "Vision 2026" and the "#FutureFresenius" initiative, which aims to make Fresenius Kabi's production network more efficient and streamlined. Financial details of the transaction were not disclosed.

Medifarma, a pharmaceutical company with a strong presence in Latin America, plans to continue the production of Laboratorio Sanderson’s existing product portfolio in Chile. Fresenius Kabi will remain active in the Chilean and South American market, as emphasized by the company in its statement.

The announcement of the sale was positively received by investors. The Fresenius share temporarily rose by 0.24 percent to 33.45 euros in XETRA trading.

With this transaction, Fresenius is implementing its strategy to focus on its core markets and competencies while simultaneously streamlining its portfolio through targeted divestitures.